Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17654722 | 0.78 | TRPV4 (0.43) | MAOAMAOBSLC6A4SLC6A2 | |
| SCHEMBL19175665 | 0.76 | HRH4 (0.46) | SLC6A4KDM4EALDH1A1GAASLC6A2 | |
| SCHEMBL9620701 | 0.75 | HTR2A (0.42) | MAOAMAOBSLC6A4KCNH2 | |
| SCHEMBL9620645 | 0.75 | HTR2A (0.42) | MAOAMAOBSLC6A4KCNH2 | |
| SCHEMBL9620706 | 0.75 | HTR2A (0.42) | MAOAMAOBSLC6A4KCNH2 | |
| SCHEMBL9620647 | 0.75 | HTR2A (0.42) | MAOAMAOBSLC6A4KCNH2 | |
| SCHEMBL19175659 | 0.74 | SLC6A2 (0.48) | SLC6A4SLC6A2SLC6A3HTR3AKCNH2 | |
| SCHEMBL19175675 | 0.73 | TSHR (0.42) | SLC6A4KDM4EALDH1A1GAASLC6A2 | |
| SCHEMBL1026069 | 0.73 | CYP2A6 (0.48) | SLC6A4KDM4EALDH1A1GAASLC6A2 | |
| SCHEMBL19175432 | 0.73 | KDM1A (0.44) | SLC6A4KDM4EALDH1A1GAAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180487-B2 | Substituted cyanoindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-23 | — | — | US | disclosed |
| US-20210087182-A1 | NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-25 | — | — | US | disclosed |
| WO-2017125530-A1 | NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087182-A1 | NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | NFKBIA, IKBKG, IKBKB | MAOA 3571/4885MAOB 2350/4885SLC6A4 4749/4885 |
| US-11180487-B2 | Substituted cyanoindoline derivatives as NIK inhibitors | NFKBIA, MAP3K14, IKBKG | MAOA 3310/4885MAOB 2863/4885SLC6A4 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.